

AGENDA

MACS® Cell and Gene Therapy Days
November 4-5, 2025

Bergisch Gladbach, Germany

MACS® Cell and Gene Therapy Days 2025:

transforming patient access through point-of-care manufacturing and analytics

▸ miltenyibiotec.com

Miltenyi Biotec

DAY 1 November 4, 2025

AGENDA

11:30 a.m. **Registration and lunch**

1:00 p.m. **Next frontiers in CGT: new indications and therapeutic strategies**

Latest clinical developments in CAR T cell therapy of autoimmunity
Fabian Müller, MD, Uniklinikum Erlangen, Erlangen, Germany

Rapid succession of graft engineering and CAR T therapies facilitated by PoC manufacturing
Wing Leung, MD, KK Women's and Children's Hospital, Singapore

Developing stem cell gene therapy for rare inflammatory disorders
Despina Eleftheriou, MD, UCL GOS Institute of Child Health, London, United Kingdom

Navigating pre-GMP and GMP-core development: lessons from the Swedish/ Norwegian experience
Anna Pasetto, PhD, Oslo University Hospital, Center for Advanced Cell Therapy (ACT), Oslo, Norway

3:00 p.m. **Break**

3:30 p.m. **Panel discussion**

Moderator:
Rene Meißner, Miltenyi Biotec, Germany

Panelists:
Franco Locatelli, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

Fabian Müller, MD, Uniklinikum Erlangen, Erlangen, Germany

Wing Leung, MD, KK Women's and Children's Hospital, Singapore

Despina Eleftheriou, MD, UCL GOS Institute of Child Health, London, United Kingdom

Anna Pasetto, PhD, Oslo University Hospital, Center for Advanced Cell Therapy (ACT), Oslo, Norway

4:30 p.m. **Company tours and networking**

Visit the Miltenyi Innovation and Technology Center (MITC) to see Miltenyi Biotec's CGT manufacturing and analytics solutions

7:30 p.m. **Dinner**

9:00 p.m. **Bus departure to hotel**

DAY 2 November 5, 2025

AGENDA

8:30 a.m. **Keynote lecture**

The long journey of CAR T cells: from hematology to oncology and autoimmune disorders
Franco Locatelli, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

9:00 a.m. **PoC manufacturing of CGT – experiences around the globe**

Academic PoC CAR T in Canada: opportunities and challenges getting to market
Natasha Kekre, MD, Ottawa Hospital Research Institute, Ottawa, Canada

IL-18-enforced CAR T cell therapy for solid tumors
Claudia Rossig, MD, University Children´s Hospital, Münster, Germany

Outcomes of low-cost, point-of-care manufactured CAR T cell therapy for B cell acute leukemia and non-hogkin lymphoblastic lymphoma in Vietnam
Nguyen Thanh Liem, MD, Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam

PoC manufacturing of CAR T therapy in Slovenia
Matjaz Sever, MD, University Clinical Center Ljubljana, Ljubljana, Slovenia

10:30 a.m. **Workshop introduction**

10:45 a.m. **Transition break**

11:00 a.m. **Workshop – PoC manufacturing and analytics**

12:00 p.m. **Lunch**

1:00 p.m. **Workshop summary and panel discussion**

Moderator:
Cristina Conforti Andreoni, PhD,
Miltenyi Biotec, Germany

Panelists:
Natasha Kekre, MD, Ottawa Hospital Research Institute, Ottawa, Canada

Claudia Rossig, MD, University Children´s Hospital, Münster, Germany

Nguyen Thanh Liem, MD, Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam

Matjaz Sever, MD, University Clinical Center Ljubljana, Ljubljana, Slovenia

Laura Palau López, Hospital Clínic de Barcelona, Barcelona, Spain

2:00 p.m. **Transforming patient access through PoC manufacturing and analytics – a Miltenyi Biotec perspective**

Joe Thuan Lim, Miltenyi Biotec, Germany

2:30 p.m. **Closing and departure**



Miltenyi Biotec

Miltenyi Biotec B.V. & Co. KG
Friedrich-Ebert-Straße 68 | 51429 Bergisch Gladbach | Germany
Phone +49 2204 8306-0 | Fax +49 2204 85197
macsde@miltenyi.com | **www.miltenyibiotec.com**

Miltenyi Biotec provides products and services worldwide.
Visit **www.miltenyibiotec.com/local** to find your nearest Miltenyi Biotec contact.

The statements and other contributions presented at the meeting and the views expressed therein are those of the attending experts and do not necessarily represent the policy or opinion of Miltenyi Biotec or any institution the respective expert may be associated with. Neither Miltenyi Biotec nor any of its directors or employees give any representation or warranty as to the reliability, accuracy, or completeness of the content thereof. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This notice must accompany any further distribution of this document.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. Copyright © 2025 Miltenyi Biotec and/or its affiliates. All rights reserved.